Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCAR-M23
- Development stage
- Discontinued
- Lead developer
- Legend Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LCAR-M23 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy designed to target mesothelin (MSLN), a cell surface glycoprotein frequently overexpressed in various solid tumors, including epithelial ovarian cancer. Developed by Legend Biotech in collaboration with Shanghai East Hospital, the therapy involves the infusion of autologous T cells genetically engineered to express a CAR specific for mesothelin. The treatment protocol typically includes a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine prior to a single infusion of the CAR-T cells. A Phase I clinical trial evaluating LCAR-M23 in patients with relapsed or refractory epithelial ovarian cancer was initiated but subsequently terminated.
- Other names
- LCAR-M23-Shanghai East Hospital-epithelial ovarian cancerLCAR-M-23-Shanghai East Hospital-epithelial ovarian cancerLCAR-M 23-Shanghai East Hospital-epithelial ovarian cancer
02
Targets
Mesothelin
Beyond the preview
Go deeper on LCAR-M23.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCAR-M23.